| Issue Date | Title | Author(s) |
| Mar-2020 | Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy | Fan, Rong; Zhou, Bin; Xu, Min; Tan, Deming; Niu, Junqi; Wang, Hao; Ren, Hong; Chen, Xinyue; Wang, Maorong; Ning, Qin; Shi, Guangfeng; Sheng, Jifang; Tang, Hong; Bai, Xuefan; Liu, Shi; Lu, Fengmin; Peng, Jie; Sun, Jian; Xie, Qing; Hou, Jinlin; Wan, Mobin; Chen, Shijun; Yu, Yanyan; Ma, Hong; Cheng, Jun; Zhang, Hongfei; Liu, Huimin; Gao, Zhiliang; Sun Yat-Sen; Dou, Xiaoguang |
| 2018 | Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B | Yu, Rui; Tan, Deming; Ning, Qin; Niu, Junqi; Bai, Xuefan; Chen, Shijun; Cheng, Jun; Yu, Yanyan; Wang, Hao; Xu, Min; Shi, Guangfeng; Wan, Mobin; Chen, Xinyue; Tang, Hong; Sheng, Jifang; Dou, Xiaoguang; Shi, Junping; Ren, Hong; Wang, Maorong; Zhang, Hongfei; Gao, Zhiliang; Chen, Chengwei; Ma, Hong; Jia, Jidong; Hou, Jinlin; Xie, Qing; Sun, Jian |
| 2013 | Baseline Quantitative Hepatitis B Core antibody is the Strongest Predictor for 2-year HBeAg seroconversion in HBeAg Positive CHB Patients Treated with Telbivudine Alone or Combined with Adefovir | Sun, Jian; Yuan, Quan; Xie, Qing; Fan, Rong; Tan, Deming; Ning, Qin; Niu, Junqi; Bai, Xuefan; Song, Liuwei; Chen, Shijun; Cheng, Jun; Yu, Yanyan; Wang, Hao; Xu, Min; Shi, Guangfeng; Wan, Mobin; Chen, Xin-Yue; Tang, Hong; Sheng, Jifang; Dou, Xiaoguang; Shi, Junping; Ren, Hong; Wang Maorong; Zhang, Hongfei; Gao, Zhiliang; Chen, Chengwei; Ma, Hong; Jia, Jidong; Xia, Ningshao; Hou, Jinlin |
| 2019 | DOUBLE NEGATIVE HBV NUCLEIC ACID (DNA-/RNA-) PREDICTS OFF-TREATMENT DURABILITY OF NUCLES(T)IDE ANALOGUE IN A PROSPECTIVE COHORT | Fan, Rong; Zhou, Bin; Xu, Min; Tan, Deming; Niu, Junqi; Wang, Hao; Ren, Hong; Chen, Xinyue; Wang, Maorong; Ning, Qin; Shi, Guangfeng; Sheng, Jifang; Tang, Hong; Bai, Xuefan; Liu, Shi; Lu, Fengmin; Peng, Jie; Sun, Jian; Xie, Qing; Hou, Jinlin |
| 2019 | Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir | Kong, Yuanyuan; Sun, Yameng; Zhou, Dialing; Wu, Xiaoning; Chen, Yongpeng; Piao, Hongxin; Lu, Lungen; Ding, Huiguo; Nan, Yuemin; Jiang, Wei; Xu, Youqing; Xie, Wen; Li, Hanwei; Feng, Bo; Shi, Guangfeng; Chen, Guofeng; Li, Hai; Zheng, Huanwei; Cheng, Jilin; Wang, Tailing; Liu, Hui; Lv, Fudong; Shao, Chen; Mao, Yimin; Sun, Jihong; Chen, Tao; Han, Tao; Han, Ying; Wan, Lin; Ou, Xiaojuan; Zhang, Hui; Jia, Jidong; You, Hong |
| 2015 | Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B | Hou, Jin-Lin; Xu, Daozheng; Shi, Guangfeng; Wan, Mobin; Goodman, Zachary; Tan, Deming; Xie, Qing; Chen, Chengwei; Wei, Lai; Niu, Junqi; Wang, Qinhuan; Ren, Hong; Wang, Yuming; Jia, Jidong; Bao, Weibin; Dong, Yuhong; Trylesinski, Aldo; Naoumov, Nikolai V. |
| 2016 | A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis | Ma, Hong; Zeng, Minde; Han, Ying; Yan, Huiping; Tang, Hong; Sheng, Jifang; Hu, Heping; Cheng, Liufang; Xie, Qing; Zhu, Youfu; Chen, Guofeng; Gao, Zhiliang; Xie, Wen; Wang, Jiyao; Wu, Shanming; Wang, Guiqiang; Miao, Xiaohui; Fu, Xiaoqing; Duan, Liping; Xu, Jie; Wei, Lai; Shi, Guangfeng; Chen, Chengwei; Chen, Minhu; Ning, Qin; Yao, Chen; Jia, Jidong |
| 2016 | A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144 | Xu, Jinghang; Yu, Yanyan; Si, Chongwen; Zeng, Zheng; Li, Jun; Mao, Qing; Zhang, Dazhi; Tang, Hong; Sheng, Ji-Fang; Chen, Xinyue; Ning, Qin; Shi, Guangfeng; Xie, Qing; Zhang, Xiquan; Dai, Jun; Xu, Zhongnan |
| 2016 | A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144 | Xu, Jinghang; Yu, Yanyan; Si, Chongwen; Zeng, Zheng; Li, Jun; Mao, Qing; Zhang, Dazhi; Tang, Hong; Sheng, Ji-Fang; Chen, Xinyue; Ning, Qin; Shi, Guangfeng; Xie, Qing; Zhang, Xiquan; Dai, Jun; Xu, Zhongnan |
| 2015 | Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients | Liang, Xieer; Cheng, Jun; Sun, Yongtao; Chen, Xinyue; Li, Tong; Wang, Hao; Jiang, Jianning; Chen, Xiaoping; Long, Hui; Tang, Hong; Yu, Yanyan; Sheng, Jifang; Chen, Shijun; Niu, Junqi; Ren, Hong; Shi, Junping; Dou, Xiaoguang; Wan, Mobin; Jiang, Jiaji; Xie, Qing; Shi, Guangfeng; Ning, Qin; Chen, Chengwei; Tan, Deming; Ma, Hong; Sun, Jian; Jia, Jidong; Zhuang, Hui; Hou, Jinlin |
| 2016 | Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study | Sun, Jian; Ma, Hong; Xie, Qing; Xie, Yao; Sun, Yongtao; Wang, Hao; Shi, Guangfeng; Wan, Mobin; Niu, Junqi; Ning, Qin; Yu, Yanyan; Zhou, Huijuan; Cheng, Jun; Kang, Wenzhen; Xie, Yi; Fan, Rong; Wei, Lai; Zhuang, Hui; Jia, Jidong; Hou, Jinlin |
